<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>30729_111</messagenumb>
		<messagesenderidentifier>VERTEXP2</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151730</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>US-VERTEX PHARMACEUTICALS INC.-2013-000572</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130114</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130123</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>US-VERTEX PHARMACEUTICALS INC.-2013-000572</companynumb>
		<primarysource>
			<reportergivename>Mary</reportergivename>
			<reporterfamilyname>Strek</reporterfamilyname>
			<reporterstreet>237 E. Hickory St</reporterstreet>
			<reportercity>Hinsdale</reportercity>
			<reporterstate>IL</reporterstate>
			<reporterpostcode>60521</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
			<studyname>Solicited Program</studyname>
			<sponsorstudynumb>Solicited - Vertex GPS</sponsorstudynumb>
			<observestudytype>3</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>VERTEXP2</senderorganization>
			<senderdepartment>Global Patient Safety</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>Sean</sendergivename>
			<senderfamilyname>Darcy</senderfamilyname>
			<senderstreetaddress>130 Waverly Street</senderstreetaddress>
			<sendercity>Cambridge</sendercity>
			<senderstate>MA</senderstate>
			<senderpostcode>02139</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<senderemailaddress>VRTXGPS_SubmissionTracking@vrtx.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>Office of Surveillence and Epidemiology</receiverdepartment>
			<receivertitle>Mr.</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receiverfax>3019183134</receiverfax>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>M-T</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19871010</patientbirthdate>
			<patientsex>1</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Cystic fibrosis</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Diabetes mellitus</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Pancreatic insufficiency</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Distal ileal obstruction syndrome</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Scoliosis</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Osteoporosis</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Attention deficit/hyperactivity disorder</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Renal failure</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Liver disorder</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Surgery</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hernia repair</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Colectomy</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Drug hypersensitivity</patientepisodename>
				<patientmedicalcomment>pruritis and rash</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>pulmonary exacerbation</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Cystic fibrosis pulmonary exacerbation</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Infective pulmonary exacerbation of cystic fibrosis</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201210</reactionstartdate>
				<reactionenddateformat>610</reactionenddateformat>
				<reactionenddate>201301</reactionenddate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pseudomonas</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Pseudomonas infection</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pseudomonas infection</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201212</reactionstartdate>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>viral respiratory infection</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Adenoviral upper respiratory infection</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Adenoviral upper respiratory infection</reactionmeddrapt>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120712</testdate>
				<testname>FEV 1</testname>
				<testresult>24</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120726</testdate>
				<testname>FEV 1</testname>
				<testresult>22</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120823</testdate>
				<testname>FEV 1</testname>
				<testresult>23</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121022</testdate>
				<testname>FEV 1</testname>
				<testresult>17</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121213</testdate>
				<testname>FEV 1</testname>
				<testresult>22</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>VX-770</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugbatchnumb>302258</drugbatchnumb>
				<drugauthorizationnumb>203188</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Vertex Pharmaceuticals Inc.</drugauthorizationholder>
				<drugstructuredosagenumb>150</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>150 mg, bid</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Cystic fibrosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120426</drugstartdate>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>VX-770</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Adenoviral upper respiratory infection</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Adenoviral upper respiratory infection</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Infective pulmonary exacerbation of cystic fibrosis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Infective pulmonary exacerbation of cystic fibrosis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pseudomonas infection</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pseudomonas infection</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ADVAIR</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FLUTICASONE PROPIONATE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>SALMETEROL XINAFOATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>PROVENTIL</medicinalproduct>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugdosagetext>2 DF, prn</drugdosagetext>
				<drugadministrationroute>055</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>SALBUTAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>AQUADEKS</medicinalproduct>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugdosagetext>1 DF, bid</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20111223</drugstartdate>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>BETACAROTENE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>BIOTIN</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>CALCIUM PANTOTHENATE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>COLECALCIFEROL</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>CYANOCOBALAMIN</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>FOLIC ACID</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>NICOTINAMIDE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>PHYTOMENADIONE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>PYRIDOXINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>RETINOL PALMITATE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>RIBOFLAVIN</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>SELENOMETHIONINE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>SODIUM</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>THIAMINE MONONITRATE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>TOCOPHEROL</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>UBIDECARENONE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>ZINC AMINO ACID CHELATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ZITHROMYCIN</medicinalproduct>
				<drugstructuredosagenumb>500</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>500 mg, MWF</drugdosagetext>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AZITHROMYCIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>SYMBICORT</medicinalproduct>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugdosagetext>2 DF, bid</drugdosagetext>
				<drugadministrationroute>055</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>BUDESONIDE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>FORMOTEROL FUMARATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CALCIUM + VITAMIN D</medicinalproduct>
				<drugstructuredosagenumb>200</drugstructuredosagenumb>
				<drugstructuredosageunit>025</drugstructuredosageunit>
				<drugdosagetext>200 IU, tid</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CALCIUM CARBONATE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>COLECALCIFEROL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CIPROFLOXACIN</medicinalproduct>
				<drugstructuredosagenumb>750</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>750 mg, bid</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CIPROFLOXACIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>COLACE</medicinalproduct>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>100 mg, qd</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DOCUSATE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>PULMOZYME</medicinalproduct>
				<drugstructuredosagenumb>2.5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>2.5 mg, qd</drugdosagetext>
				<drugadministrationroute>055</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DORNASE ALFA</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>DRISDOL</medicinalproduct>
				<drugstructuredosagenumb>50000</drugstructuredosagenumb>
				<drugstructuredosageunit>025</drugstructuredosageunit>
				<drugdosagetext>50000 IU, qw</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ERGOCALCIFEROL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>FERROUS SULFATE</medicinalproduct>
				<drugstructuredosagenumb>325</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>325 mg, tid</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FERROUS SULFATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>FLONASE</medicinalproduct>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugdosagetext>1 DF, bid</drugdosagetext>
				<drugadministrationroute>045</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FLUTICASONE PROPIONATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>GLUCAGON</medicinalproduct>
				<drugdosagetext>UNK, prn</drugdosagetext>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>GLUCAGON</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>HUMALOG</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute>058</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INSULIN LISPRO</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>NOVOLOG</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute>058</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INSULIN ASPART</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CLARITIN</medicinalproduct>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>10 mg, qd</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LORATADINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>COZAAR</medicinalproduct>
				<drugstructuredosagenumb>25</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>25 mg, qd</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LOSARTAN POTASSIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>REMERON</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>MIRTAZAPINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ZYPREXA</medicinalproduct>
				<drugstructuredosagenumb>5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>5 mg, qd</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>OLANZAPINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>PRILOSEC</medicinalproduct>
				<drugstructuredosagenumb>40</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>40 mg, qd</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>OMEPRAZOLE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>RISPERDAL</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>RISPERIDONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ACTIGALL</medicinalproduct>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>300 mg, bid</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>URSODEOXYCHOLIC ACID</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>VITAMIN A</medicinalproduct>
				<drugdosagetext>UNK, qd</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>RETINOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ZENPEP</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PANCRELIPASE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>A serious, solicited report of pseudomonas and pulmonary exacerbation was received from a consumer in the UNITED STATES concerning a 25 year old, male patient.

On 26 April 2012, the patient initiated dosing with Kalydeco (ivacaftor) 150mg every 12 hours for the treatment of cystic fibrosis.

In Dec 2012, the patient was hospitalized for a pulmonary exacerbation. While in the hospital, the patient was treated for pseudomonas with TOBI (tobramycin). The patient was discharged after 10 days and was reported to be doing well at the time of his check-up on 10 Jan 2012.

The patient continued Kalydeco therapy.

Follow-up information was received from the treating physician on 23 Jan 2012: The physician reported that the event of pulmonary exacerbation started in Oct 2012 with a prior hospitalization lasting from 23 Oct 2012 through 28 Oct 2012. The patient had been treated for the event with 2 weeks of tobramycin and cefepime; however, after discharge the patient was found to be non-compliant with Kalydeco and possibly other medications. The patient soon began experiencing symptoms of rhinorrhea, congestion, sore throat, shortness of breath, worsening cough productive of green sputum, fever, sore throat, headache, weakness, and chills. Eventually, he was admitted to the hospital again from 14 Dec 2012 to 21 Dec 2012 for the pulmonary exacerbation. The patient was again treated with cefepime and tobramycin, this time for 1 week's duration. Upon discharge, the patient was recommended to continue taking concomitant medications as prescribed and by 10 Jan 2013 the patient was fully recovered.

The reporter suspected the pulmonary exacerbation was triggered by a viral respiratory infection.

The patient's medical history included diabetes mellitus, pancreatic insufficiency, distal ileal obstruction syndrome, scoliosis, osteoporosis, attention deficit/hyperactivity disorder, renal failure, liver disorder, vascular surgery, hernia repair, colectomy, and drug allergy to vancomycin. 
Concomitant medications included ADVAIR, PROVENTIL (albuterol), AQUADEKS, ZITHROMYCIN (azithromycin), SYMBICORT (budesonide-formoterol), CALCIUM + VITAMIN D, CIPROFLOXACIN, COLACE (docusate), PULMOZYME (dornase alfa), DRISDOL (ergocalciferol), FERROUS SULFATE, FLONASE (fluticasone), GLUCAGON, HUMALOG, NOVOLOG (insulin aspart), CLARITIN (lortadine), COZAAR (losartan), REMERON (mirtazapine), ZYPREXA (olanzapine), PRILOSEC (omeprazole), RISPERDAL (risperidone), ACTIGALL (ursodiol), VITAMIN A, and ZENPEP.</narrativeincludeclinical>
				<sendercomment>The events of pseudomonas infection, adenoviral upper respiratory infection and  infective pulmonary exacerbation of cystic fibrosis are considered unexpected for Kalydeco (ivacaftor). Underlying cystic fibrosis disease with diabetes mellitus, history of renal failure and liver disorder in presence of altered immune state is possible alternative etiology for these events.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
